ES2708723T3 - Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo - Google Patents

Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo Download PDF

Info

Publication number
ES2708723T3
ES2708723T3 ES12826376T ES12826376T ES2708723T3 ES 2708723 T3 ES2708723 T3 ES 2708723T3 ES 12826376 T ES12826376 T ES 12826376T ES 12826376 T ES12826376 T ES 12826376T ES 2708723 T3 ES2708723 T3 ES 2708723T3
Authority
ES
Spain
Prior art keywords
compound
alkyl
pain
variants
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12826376T
Other languages
English (en)
Spanish (es)
Inventor
Daniele Piomelli
Guillermo Moreno-Sanz
Tiziano Bandiera
Marco Mor
Giorgio Tarzia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Degli Studi Di Parma, University of
Degli Studi Di Urbino Carlo Bo, University of
Universita degli Studi di Parma
Universita degli Studi di Urbino "Carlo Bo"
Fondazione Istituto Italiano di Tecnologia
University of California Berkeley
University of California San Diego UCSD
Original Assignee
Degli Studi Di Parma, University of
Degli Studi Di Urbino Carlo Bo, University of
Universita degli Studi di Parma
Universita degli Studi di Urbino "Carlo Bo"
Fondazione Istituto Italiano di Tecnologia
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degli Studi Di Parma, University of, Degli Studi Di Urbino Carlo Bo, University of, Universita degli Studi di Parma, Universita degli Studi di Urbino "Carlo Bo", Fondazione Istituto Italiano di Tecnologia, University of California Berkeley, University of California San Diego UCSD filed Critical Degli Studi Di Parma, University of
Application granted granted Critical
Publication of ES2708723T3 publication Critical patent/ES2708723T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES12826376T 2011-08-19 2012-08-17 Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo Active ES2708723T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525636P 2011-08-19 2011-08-19
PCT/US2012/051478 WO2013028570A2 (en) 2011-08-19 2012-08-17 Meta-substituted biphenyl peripherally restricted faah inhibitors

Publications (1)

Publication Number Publication Date
ES2708723T3 true ES2708723T3 (es) 2019-04-10

Family

ID=47747054

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12826376T Active ES2708723T3 (es) 2011-08-19 2012-08-17 Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo

Country Status (12)

Country Link
US (1) US9745255B2 (OSRAM)
EP (1) EP2744778B1 (OSRAM)
JP (1) JP6092870B2 (OSRAM)
KR (1) KR102079404B1 (OSRAM)
CN (1) CN104203906B (OSRAM)
AU (1) AU2012299060B2 (OSRAM)
BR (1) BR112014003886B1 (OSRAM)
CA (1) CA2844812C (OSRAM)
DK (1) DK2744778T3 (OSRAM)
ES (1) ES2708723T3 (OSRAM)
MX (1) MX354772B (OSRAM)
WO (1) WO2013028570A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100485727B1 (ko) * 2004-06-24 2005-04-27 주식회사 바이오리더스 폴리감마글루탐산-비타민 복합체 및 그 용도
ES2708723T3 (es) 2011-08-19 2019-04-10 Univ California Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo
WO2014023325A1 (en) * 2012-08-06 2014-02-13 Fondazione Istituto Italiano Di Tecnologia Multitarget faah and cox inhibitors and therapeutical uses thereof
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
CN108348468A (zh) * 2015-08-11 2018-07-31 Eyesiu医疗股份有限公司 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒
WO2017197240A1 (en) * 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
MY172113A (en) 2017-07-05 2019-11-14 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
SG10201807034XA (en) 2017-09-05 2019-04-29 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
GB201802326D0 (en) 2018-02-13 2018-03-28 Ucl Business Plc Gene therapy
US12023332B2 (en) 2018-03-05 2024-07-02 Wylder Nation Foundation Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
AU2020206722A1 (en) * 2019-01-10 2021-07-29 Travecta Therapeutics Pte. Ltd. Anandamide compounds
US20230313196A1 (en) * 2020-07-23 2023-10-05 John Mansell Compositions and methods for treating pain and anxiety disorders
CN120965462A (zh) * 2025-10-17 2025-11-18 四川奥邦古得药业有限公司 用于生产3,5-二醚戊苯的方法及其在制备3,5-二羟基戊苯中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325889A (en) 1978-08-04 1982-04-20 Bayer Aktiengesellschaft Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid)
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5559410A (en) 1992-12-17 1996-09-24 Valeo Systemes D'essuyage Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
AU731672B2 (en) 1996-12-02 2001-04-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating bipolar disorders
GB9701453D0 (en) 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
NZ506465A (en) 1998-02-26 2003-08-29 Akzo Nobel Nv Derivatives of azetidine and pyrrolidine
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US20030134894A1 (en) 1999-04-07 2003-07-17 Daniele Piomelli Methods of treating mental diseases, inflammation and pain
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
AU2003237882B2 (en) 2002-05-16 2010-04-08 Sunovion Pharmaceuticals Inc. Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
FR2842808B1 (fr) 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
AU2003279877B2 (en) * 2002-10-07 2010-05-20 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
FR2850377B1 (fr) 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
US9316633B2 (en) 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
US20080119549A1 (en) * 2006-11-20 2008-05-22 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
TW200948805A (en) 2008-03-07 2009-12-01 Sigma Tau Ind Farmaceuti Enol carbamate derivatives as modulators of fatty acid amide hydrolase
PT2488486T (pt) 2009-10-13 2019-11-05 Ligand Pharm Inc Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos
WO2012015704A2 (en) * 2010-07-28 2012-02-02 The Regents Of The University Of California Peripherally restricted faah inhibitors
WO2012167133A2 (en) 2011-06-01 2012-12-06 The Regents Of The University Of California Inhibitors of anandamide transport and their therapeutic uses
ES2708723T3 (es) 2011-08-19 2019-04-10 Univ California Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos

Also Published As

Publication number Publication date
MX354772B (es) 2018-03-21
EP2744778B1 (en) 2019-01-16
BR112014003886A8 (pt) 2018-01-23
HK1198644A1 (en) 2015-05-22
WO2013028570A3 (en) 2013-04-18
BR112014003886A2 (pt) 2017-03-21
AU2012299060B2 (en) 2017-06-01
CN104203906B (zh) 2018-03-13
DK2744778T3 (en) 2019-03-04
EP2744778A2 (en) 2014-06-25
US9745255B2 (en) 2017-08-29
WO2013028570A2 (en) 2013-02-28
CA2844812C (en) 2019-10-22
JP2014527532A (ja) 2014-10-16
JP6092870B2 (ja) 2017-03-08
MX2014001966A (es) 2015-04-08
KR20150100485A (ko) 2015-09-02
EP2744778A4 (en) 2015-04-08
KR102079404B1 (ko) 2020-02-19
NZ622480A (en) 2016-05-27
CN104203906A (zh) 2014-12-10
CA2844812A1 (en) 2013-02-28
AU2012299060A1 (en) 2014-04-03
US20140288170A1 (en) 2014-09-25
BR112014003886B1 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
ES2708723T3 (es) Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo
RU2583435C2 (ru) Ингибиторы faah периферически-ограниченного действия
CA2740087C (en) Gaba conjugates and methods of use thereof
JP7021098B2 (ja) 神経筋、神経変性、自己免疫、発達、外傷性脳損傷、震とう、ドライアイ疾患および/または代謝性疾患のdnpおよびdnpプロドラッグ処置
US9321743B2 (en) Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase
BRPI0720252A2 (pt) Uso de pró-fármacos de análogos de gaba para tratar doenças
US20130281490A1 (en) Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA)
CN105503741A (zh) 一种氨基甲酰尿嘧啶衍生物及其应用
HK1198644B (en) Meta-substituted biphenyl peripherally restricted faah inhibitors
NZ622480B2 (en) Meta-substituted biphenyl peripherally restricted faah inhibitors